(Cannabidiol + dronabinol) sublingual is under clinical development by Zelira Therapeutics and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Cannabidiol + dronabinol) sublingual’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Cannabidiol + dronabinol) sublingual overview

Fixed dose combination of dronabinol and cannabidiol is under development for the treatment of childhood autism. They act by targeting cannabinoid receptors CB1 and CB2. It is administered through sublingual route.

Zelira Therapeutics overview

Zelira Therapeutics develops cannabis healthcare therapies and products. The company offers cannabis products for the treatment of insomnia, autism and opioid reduction. Zelira Therapeutics is headquartered in Perth, Western Australia, Australia.

For a complete picture of (Cannabidiol + dronabinol) sublingual’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.